<DOC>
	<DOCNO>NCT01756768</DOCNO>
	<brief_summary>This open-label , single-center study evaluate mass-balance pharmacokinetics PD-0332991 approximately 6 healthy male subject receive single oral 125 mg dose PD-0332991 containing approximately 100 microcuries [ 14C ] -PD-0332991 . Subjects checked research unit approximately 12 hour prior dose remain house great 90 % administer radioactivity collect bodily excreta less 1 % administer radioactivity recover excreta consecutive day . This study investigate extent involvement renal hepatic system elimination PD-0332991 seek identify compound 's major metabolite .</brief_summary>
	<brief_title>A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption , Metabolism , And Excretion Of 14C Palbociclib ( PD-0332991 ) In Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Palbociclib</mesh_term>
	<criteria>A Healthy Male Volunteer 18 55 year age inclusive A Body Mass Index ( BMI ) 17.5 30.5 kg/m2 total body weight &gt; 50kg A sign informed consent document Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . A positive urine drug urine cotinine screen . Concurrent use herbal prescription medication treatment investigational drug within 30 day 5 halflives precede first dose study medication . Subjects whose occupation require exposure radiation monitoring radiation exposure . Subjects history irregular bowel movement ( eg , regular episode diarrhea constipation , irritable bowel syndrome ( IBS ) lactose intolerance ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Mass Balance study</keyword>
	<keyword>Radio-labeled dose</keyword>
	<keyword>PD-0332991</keyword>
</DOC>